Skip to main content
. 2018 Apr 19;13(4):e0192845. doi: 10.1371/journal.pone.0192845

Fig 4. Activation of inflammasomes in PBMCs from HIV-1-infected donors.

Fig 4

LPS-primed PBMCs were treated with inflammasomes agonists (ATP for NLRP3 (A), MDP for NLRP1 (B), Flagellin for NLRC4 (C) and poly(dA:dT) for AIM2 (D), and the IL-1β release was quantified by ELISA in the supernatants. Fold increase is referred to primed cells (cells treated only with 50 pg/mL LPS). The results are presented as median and interquartile ranges. Statistical comparison between groups was performed using a Mann-Whitney U test with a confidence level of 95%. Significant differences are indicated at the top of the figure (*p <0.05).